



**Report on the WHO forms  
for declaration of interests submitted by  
MSIF Essential Medicine Panel (MEMP)  
on disease-modifying drugs for multiple sclerosis  
in low resource-settings**

**Update**

**May, 31 2022**

by A.J. Fauci, C. Petrini, G.F. Gensini

*Istituto Superiore di Sanità*

**Table of contents**

1. Introduction .....3  
2. Results of the assessment .....3  
    2.1 Risk level 2 - measure 2a: full participation in the work with public disclosure of interest .....3  
List of Annexes .....4

## 1. Introduction

This document is an update of the Report on the WHO forms for declaration of interests declared by MSIF Essential Medicine Panel (MEMP) on disease-modifying drugs for multiple sclerosis in low resource-settings, submitted on march 2022.

The following interests were communicated to ISS by means of an email sent by Mrs Joanna Laurson on May 17 2022:

- Dina Jacobs: Grant funding from EMD Serono for a Fellowship at Penn.
- Riley Bove: Consulting fees from Jansen (3/2022) and TG Therapeutics (4/2022).

Moreover, this document includes an amendment to the above mentioned Report by enclosing the new guideline's PICO's with the updated list of DMTs (Annex 1).

## 2. Results of the assessment

### 2.1 Risk level 2 - measure 2a: full participation in the work with public disclosure of interest

The interests shown in Table 1 are considered as potentially relevant (risk level 2) with application of measure 2a (participation with disclosure). Although the interests are specific to the guideline scope and refer mainly to activities paid by Pharma, they nevertheless are not related to the specific DTMs evaluated by the guideline.

**Therefore, the involved experts are entitled to fully participate in the guideline work with public disclosure of the relevant interests in the guideline document or on the website following the publication of the recommendation.**

Table 1 List of interests assessed as Risk level 2 - measure 2a: full participation in the work with public disclosure of the interest

Expert N.	Name	Role	Col form item	Declared interest	Organization	Belongs to	Amount	Period
45	Dina Jacobs	panel member	1b consulting	Grant funding from for a Fellowship at Penn	EMD Serono	institutional	–	–
44	Riley Bove	panel member	1b consulting	Consulting fees for new MS therapies	Jansen	personal	–	3/2022
44	Riley Bove	panel member	1b consulting	Consulting fees new MS therapies	TG Therapeutics	personal	–	4/2022

## List of Annexes

Annex 2 – MSIF Essential medicines Panel (MEMP) guideline PICO questions, march 22 2022.